title: Recent advances in the treatment of eosinophilic esophagitis.
abstract: First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of the current literature on EoE has been published in the last 3 years, signaling both a rising incidence and increased recognition of this disorder. Treatment options available for patients with EoE include dietary management and/or pharmacologic therapy. An individualized approach to treatment is preferred, with an emphasis on patient-parental preference. The objective of this article is to discuss the current and future treatment options for EoE.
authors.affiliation: University of Colorado Denver School of Medicine, Denver, CO, USA; The Children's Hospital Denver, 13123 East 16th Avenue, B290, Aurora, CO 80016, USA.
authors.forename: Shauna
authors.initials: S
authors.lastname: Schroeder
authors.forename: Dan
authors.initials: D
authors.lastname: Atkins
authors.forename: Glenn T
authors.initials: GT
authors.lastname: Furuta
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004035:Diet Therapy / Q000639:trends; D057765:Eosinophilic Esophagitis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D018793:Interleukin-13 / Q000276:immunology; D015848:Interleukin-5 / Q000276:immunology; D009092:Mucous Membrane / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D057240:Patient Preference; D057285:Precision Medicine; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D058408:Th1-Th2 Balance / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D018793:Interleukin-13; D015848:Interleukin-5; D054328:Proton Pump Inhibitors